Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (SLSNLDFRL) Complex Protein (Monomer, MALS verified)

Cat. No. / Size
Price
Availability
Qty
HLL-H82E3-25ug
$125.00
In Stock - Delivery in 1-2 business days
HLL-H82E3-200ug
$700.00
HLL-H82E3
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

HLA-A*0201 & B2M & Vaccinia virus (SLSNLDFRL)

Source

Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (SLSNLDFRL) Complex Protein (HLL-H82E3) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLSNLDFRL peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & SLSNLDFRL).

Predicted N-terminus: Gly 25 & Ile 21

Molecular Characterization

Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (SLSNLDFRL) Complex Protein is produced by co-expression of HLA and B2M loaded with Vaccinia virus peptide.

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 40-43 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Labeling

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Purity

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Background

Among the nonvirion proteins of the vaccinia virus (VACV), a 94-kDa long protein is most abundantly present; the protein is a truncated form of the 150-kDa A-type inclusion (ATI) protein of the cowpox virus encoded by the ati gene. This VACV protein does not form intracellular ATIs, being as it is a major immunogen upon infection/immunization of humans or animals with the VACV. variants demonstrated that the mutant LIVPΔati elicits a stronger protective response compared to the parent LIVP. The human HLA-A*0201 Vaccinia virus F11L (SLSNLDFRL) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and SLSNLDFRL peptide of the vaccinia virus.